MedTrace Logo

A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

NCT06504589 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2025-10-01

No results posted yet for this study

Summary

The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to inform CF research, help design CF clinical trials and support the development of new treatments for people with CF who do not take CFTR modulators.

Another goal of this study is to learn about research involvement for people with CF who do not take CFTR modulators, engage them in research, and give them an opportunity to learn about what is involved in participating in a CF research study.

Conditions

Sponsors & Collaborators

  • Washington University School of Medicine

    collaborator OTHER

  • Florida State University

    collaborator OTHER

  • University of North Carolina, Chapel Hill

    collaborator OTHER

  • University of Toronto

    collaborator OTHER

  • Cystic Fibrosis Foundation

    collaborator OTHER

  • Nicole Hamblett

    lead OTHER

Principal Investigators

  • Deepika Polineni, MD, MPH · Washington University School of Medicine

  • Nicole Mayer-Hamblett, PhD · Seattle Children's Hospital

  • Scott Donaldson, MD · University of North Carolina, Chapel Hill

  • Felix Ratjen, MD · University of Toronto

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-18
Primary Completion
2029-08-14
Completion
2029-08-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06504589 on ClinicalTrials.gov